Phase II Multicentric Study of Digoxin Per os in Classic or Endemic Kaposi' s Sarcoma

Inclusion Criteria: * Age \> 18 years \<à 80 years * Classic or endemic histologically confirmed Kaposi's Sarcoma (KS) * Progressive disease * KS with more than 10 lesions or involving more than one limb segment or with involvement \>3% body surface * KS with at least 4 lesions ≥5mm * Patients should have at least 2 others cutaneous tumor available for repeated pharmacodynamics evaluation * At least 4 weeks wash out for all KS specific therapies including chemotherapy and immunotherapy * Signed informed consent Exclusion Criteria: * Symptomatic visceral lesions * Eastern Cooperative Oncology Group ( ECOG) performance status \> 1 * Life expectancy of ≤ 6 months * Patients already receiving digoxin * hepatic dysfunction defined as serum bilirubin\>25 µm/l, transaminases \> 3.0 times the upper limit of normal (ULN) (5ULN in cases of liver metastases) * bone marrow dysfunction defined as absolute neutrophil count\<1500/mcl, platelets\<150000/mcl or hemoglobin\<8g/dL * renal failure with creatinine clearance\< 40ml/mn * HIV positive, active infectious hepatitis, type A, B or C * Uncontrolled systemic infection * Pregnant or lactating women * Presence of any of the following on electrocardiogram (ECG): atrial arrhythmias, including atrial fibrillation and flutter with Wolff-Parkinson-White syndrome; auricular ventricular (AV) block; heart rate \< 60 beats/minute and \> 100 beats/minute; ventricular fibrillation; ventricular tachycardia; premature ventricular contractions. * History of or current cardiac arrythmia including sinus node disease, history of AV Block, accessory AV pathway (Wolff-Parkinson-White Syndrome), history myocardial infarction, any significant valvulopathy. * Electrolyte imbalance (hypokalemia, hypo- or hypercalcemia, hypomagnesemia) * Severe pulmonary disease and hypoxia * Medical conditions such as uncontrolled hypertension, uncontrolled diabetes mellitus, hypothyroidism or hyperthyroidism, which would, in the opinion of the investigator, make this protocol unreasonably hazardous. * Major thoracic or abdominal surgery within the prior 3 weeks. * GI tract disease resulting in an inability to take oral medication, malabsorption syndrome, a requirement for IV alimentation, prior surgical procedures affecting absorption, uncontrolled inflammatory GI disease (e.g., Crohn's, ulcerative colitis). * Immunosuppressive regimen should not be allowed including corticosteroids * Use of any prohibited concomitant medications: * the calcium channel blockers diltiazem or verapamil; * Class I and III cardiac arrhythmic agents (such as quinidine, amiodarone); * beta-blockers (such as atenolol, metoprolol); * indomethacin (Indocin); * calcium carbonate antacids (e.g., Maalox, Tums, Rolaids); * Calcium * omeprazole; * antidiarrheal adsorbents (kaolin and pectin); * antibiotics P450 inhibitors clarithromycin, erythromycin telithromycin and other P450 inhibitors./such as Ritonavir) * Persistent Grade \>2 treatment-related toxicity from prior therapy * History of any digoxin-related or drug induced anaphylactic reaction * Use of any other investigational agent * Patient without health insurance coverage * Patient under guardianship * Enrollment into a clinical trial within last 4 weeks